# SereNeuro reports promising results for iPSC-derived therapy SN101 for chronic osteoarthritis pain

**Category:** Health
**Source:** [https://www.sciencedaily.com/releases/2025/12/251215098765.htm](https://www.sciencedaily.com/releases/2025/12/251215098765.htm)
**Publisher:** ScienceDaily
**Published:** 2025-12-15
**Scraped (UTC):** 2025-12-25T07:00:11+00:00

## Summary
SereNeuro Therapeutics announced encouraging data for SN101, a first-in-class iPSC-derived therapy intended to treat chronic osteoarthritis pain while protecting joint tissue, reported mid-December 2025.

## Full Article
*(Article text could not be extracted. Visit source link above.)*

---

*Content scraped from public sources with attribution. Users assume all risk.*  
*Auto-generated by [Perplexity News Tracker](https://github.com/myidkd1-coder/perplexity-news-tracker)*